Alopecia Treatment Safe for Breast Cancer Survivors Alopecia Treatment Safe for Breast Cancer Survivors
Spironolactone is safe for the treatment of alopecia in breast cancer survivors taking endocrine therapy, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 26, 2020 Category: Consumer Health News Tags: Dermatology News Source Type: news
Study Identifies Barriers to Endocrine Therapy Adherence in Breast Cancer Survivors
In this study, researchers found that 59% of the participants reported at least 1 barrier to endocrine therapy adherence, though over half reported that taking endocrine therapy was a joint decision between themselves and their doctor. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Certain factors linked with discontinuing breast cancer therapy
(Wiley) For women with hormone receptor-positive breast cancer, long-term endocrine therapy can greatly reduce the risk of recurrence. Many women, especially those in underserved populations, do not continue treatment, however. A new Psycho-Oncology study uncovers some of the factors that may be involved. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 19, 2020 Category: Cancer & Oncology Source Type: news
Oral Vinorelbine With Endocrine Therapy for Breast Cancer Oral Vinorelbine With Endocrine Therapy for Breast Cancer
Is the combination of oral metronomic vinorelbine plus letrozole safe and effective for ER+ breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 28, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Breast Cancer Index and Extended Endocrine Therapy Benefit Breast Cancer Index and Extended Endocrine Therapy Benefit
Might the Breast Cancer Index effectively predict benefit from extended endocrine treatment? Data from the aTTom trial provides insight.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
10-year results of NRG Oncology/NSABP B-42 trial
(NRG Oncology) In the updated results from NRG Oncology/NSABP B-42 trial through 10 years of observation, extending letrozole therapy for additional five years after five years of adjuvant endocrine therapy resulted in a statistically significant improvement in the 10-year disease-free survival (DFS) of postmenopausal women with hormone-receptor-positive breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 12, 2019 Category: Cancer & Oncology Source Type: news
Targeted therapy drug helps women with aggressive breast cancer live longer
A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy significantly improves overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common types of the disease.The findings also show the combination treatment is beneficial at the time of recurrence and should become a first-line option in postmenopausal women with HR+/HER2- advanced breast cancer.The study was published today in the New England Journal of Medicine and presented earlier this year at the European Society for Medical Oncology Congress in...
Source: UCLA Newsroom: Health Sciences - December 11, 2019 Category: Universities & Medical Training Source Type: news
Addition of S-1 to Endocrine Therapy Postoperatively Improves Survival in HR+, HER2- Breast Cancer
Adjuvant therapy with S-1, an oral fluoropyrimidine-based drug, plus endocrine therapy postoperatively significantly increased invasive disease-free survival (IDFS) in patients with HR-positive, HER2-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 11, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Immune checkpoint therapy for ER+ breast cancers, a missed opportunity?
(Baylor College of Medicine) A subset of endocrine therapy-resistant luminal B breast cancers activates immune responses that could be amenable to manipulation with immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2019 Category: Cancer & Oncology Source Type: news
Endocrine Therapy Lowers QOL for Breast Cancer Patients
Effects of chemotherapy found to be more transient in comparison (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - November 25, 2019 Category: Psychiatry Tags: Gynecology, Oncology, Pharmacy, Psychiatry, Journal, Source Type: news
Endocrine Therapy Lowers QOL for Breast Cancer Patients
MONDAY, Nov. 25, 2019 -- Endocrine therapy reduces the quality of life of breast cancer patients, especially for postmenopausal women, according to a study recently published in the Annals of Oncology.
Arlindo R. Ferreira, M.D., of the Institut... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 25, 2019 Category: Pharmaceuticals Source Type: news
CDK4/6 Combo Better Than Chemo in Advanced Breast Cancer CDK4/6 Combo Better Than Chemo in Advanced Breast Cancer
A new study confirms that a CDK4/6 blocker plus endocrine therapy is better than chemotherapy in young women with HR+, HER2- metastatic disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma
In a new study, patients with HR+/HER2- early stage breast cancer completed 2 years of adjuvant palbociclib with a similar toxicity profile as that observed in the metastatic setting.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Ask About Sex Life in Breast Cancer Patients on Endocrine Tx Ask About Sex Life in Breast Cancer Patients on Endocrine Tx
A new study shows that almost all postmenopausal women taking endocrine therapy to prevent breast cancer relapses report adverse effects on sexual function.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 31, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Addition of Abemaciclib to Fulvestrant Improves OS in HR+, HER2- Advanced Breast Cancer
The combined use of a CDK4/6 inhibitor with endocrine therapy yielded a 9.4-month median OS benefit among patients. (Source: CancerNetwork)
Source: CancerNetwork - October 18, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news
